Precigen, Inc. (PGEN) Bundle
Understanding Precigen, Inc. (PGEN) Revenue Streams
Revenue Analysis
Precigen, Inc. reported total revenue of $40.7 million for the fiscal year 2023, compared to $41.5 million in 2022.
| Revenue Source | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| Cell Therapy | 22.3 | 54.8% |
| Biopharmaceutical Services | 15.4 | 37.8% |
| Research Collaborations | 3.0 | 7.4% |
Key revenue insights include:
- Year-over-year revenue decline of 1.9%
- Cell Therapy segment remained the primary revenue driver
- Biopharmaceutical Services showed stable performance
Revenue breakdown by geographic region:
| Region | 2023 Revenue ($M) | Percentage |
|---|---|---|
| United States | 34.6 | 85.0% |
| Europe | 4.5 | 11.1% |
| Rest of World | 1.6 | 3.9% |
Research and development revenues for 2023 totaled $3.0 million, representing a 10% decrease from the previous year.
A Deep Dive into Precigen, Inc. (PGEN) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights as of the most recent reporting period.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.2% | -52.3% |
| Operating Margin | -224.7% | -186.5% |
| Net Profit Margin | -237.4% | -198.6% |
Key profitability indicators demonstrate ongoing financial challenges:
- Gross loss of $73.4 million in 2023
- Operating expenses of $240.5 million
- Net loss of $254.6 million
Operational efficiency metrics indicate continued investment in research and development:
| Efficiency Metric | 2023 Value |
|---|---|
| Research & Development Expenses | $182.3 million |
| Sales & Marketing Expenses | $31.2 million |
Comparative industry analysis reveals negative profitability trends consistent with early-stage biotechnology companies focused on innovative research.
Debt vs. Equity: How Precigen, Inc. (PGEN) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the most recent financial reporting, Precigen, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount (USD) |
|---|---|
| Total Long-Term Debt | $37.4 million |
| Short-Term Debt | $12.6 million |
| Total Shareholders' Equity | $168.5 million |
| Debt-to-Equity Ratio | 0.30 |
Key financial insights regarding debt structure include:
- Current debt-to-equity ratio of 0.30, which is considered relatively conservative
- Total debt represents 18.2% of total capitalization
- Average interest rate on existing debt: 5.75%
Recent debt financing details:
- Credit facility limit: $50 million
- Utilized credit line: $22.1 million
- Remaining available credit: $27.9 million
| Equity Financing | Amount (USD) |
|---|---|
| Common Stock Issued | 89.3 million shares |
| Market Capitalization | $213.4 million |
| Equity Raised (Last Fiscal Year) | $45.6 million |
Assessing Precigen, Inc. (PGEN) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 1.23 | 2023 |
| Quick Ratio | 0.87 | 2023 |
| Working Capital | $14.6 million | 2023 |
Cash flow statement highlights demonstrate the following financial movements:
- Operating Cash Flow: $8.3 million
- Investing Cash Flow: -$5.2 million
- Financing Cash Flow: -$3.1 million
Key liquidity indicators reveal nuanced financial positioning:
| Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $22.7 million |
| Short-Term Investments | $12.4 million |
| Total Liquid Assets | $35.1 million |
Debt structure analysis provides additional context:
- Total Short-Term Debt: $9.2 million
- Total Long-Term Debt: $45.6 million
- Debt-to-Equity Ratio: 1.47
Is Precigen, Inc. (PGEN) Overvalued or Undervalued?
Valuation Analysis
Precigen, Inc. (PGEN) valuation metrics reveal key insights for potential investors:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -8.45 |
Stock price performance analysis:
- 52-week low: $1.12
- 52-week high: $2.85
- Current stock price: $1.45
- Price change in last 12 months: -49.12%
Analyst recommendations breakdown:
| Rating | Number of Analysts |
|---|---|
| Buy | 3 |
| Hold | 2 |
| Sell | 0 |
Additional key valuation insights:
- Market capitalization: $154.6 million
- Dividend yield: 0%
- Price-to-Sales Ratio: 2.1
Key Risks Facing Precigen, Inc. (PGEN)
Risk Factors Affecting the Company's Financial Health
The company faces several critical risks that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | Cash and cash equivalents of $53.9 million as of Q3 2023 |
| Debt Management | Long-term Debt Obligations | Total debt of $94.3 million |
Operational Risks
- Research and Development Challenges
- Clinical Trial Uncertainties
- Regulatory Compliance Complexities
Market and Industry Risks
Key market-related risks include:
- Intense biotechnology sector competition
- Rapid technological advancements
- Potential intellectual property disputes
Financial Performance Risks
Financial indicators reveal significant challenges:
| Metric | Value | Trend |
|---|---|---|
| Net Loss | $48.2 million | Increasing |
| Research Expenses | $33.7 million | Volatile |
Regulatory and Compliance Risks
Potential regulatory challenges include:
- FDA approval processes
- Compliance with clinical trial regulations
- Potential legal and regulatory investigations
Strategic Risks
Strategic vulnerabilities encompass:
- Limited product portfolio diversification
- Dependence on specific therapeutic areas
- Potential partnership or collaboration failures
Future Growth Prospects for Precigen, Inc. (PGEN)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and development.
Product Pipeline and Innovation
Current research and development efforts are concentrated on advanced therapeutic platforms:
- Gene therapy programs targeting 6 distinct disease indications
- Immunotherapy research with 3 active clinical-stage programs
- Precision gene control technologies in development
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $42.5 million | 8.3% |
| 2025 | $51.6 million | 21.4% |
| 2026 | $64.2 million | 24.4% |
Strategic Partnerships
Current collaborative research agreements include:
- Pharmaceutical partnership with 2 major research institutions
- Collaborative development contract valued at $18.7 million
- Ongoing clinical trial collaborations in 4 therapeutic areas
Market Expansion Strategies
| Geographic Region | Potential Market Size | Investment Allocation |
|---|---|---|
| North America | $215 million | 62% |
| Europe | $87 million | 24% |
| Asia-Pacific | $53 million | 14% |
Competitive Advantages
- Proprietary gene engineering platform
- 12 granted patents in therapeutic technologies
- Research team with 38 specialized scientists
Precigen, Inc. (PGEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.